Recent developments in the treatment of bladder cancer

Advances in Experimental Medicine and Biology

Volumn 539 A, Issue , 2004, Pages 3-14

  Lance, Raymond S ^a   Grossman, H Barton ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BASEMENT MEMBRANE ANTIBODY; BCG VACCINE; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; DOXORUBICIN; HYALURONIC ACID; MONOCLONAL ANTIBODY; PROTEIN P53; PYRIDOXINE; RETINOL; TELOMERASE;

BCG VACCINATION; BLADDER CARCINOMA; CANCER CYTODIAGNOSIS; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CYSTECTOMY; DIAGNOSTIC TEST; DISEASE MARKER; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; IMAGE ANALYSIS; LABORATORY TEST; MAINTENANCE THERAPY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR SUPPRESSOR GENE; URINARY DIVERSION; URINE CYTOLOGY; BLADDER TUMOR; REVIEW;

MYCOBACTERIUM BOVIS BCG;

CARCINOMA, TRANSITIONAL CELL; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 2342489458     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (58)

1. Alexandroff AB, Jackson AM, O'Donnell MA, James K: BCG immunotherapy of bladder cancer: 20 years on. Lancet, 353:1689, 1999.
2. Badalament RA, Hermansen DK, Kimmel M, Gay H Herr, HW Fair, WR Whitmore, WF, Melamed MR: The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer, 60:1423, 1987.
3. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM: The accuracy of urinary cytology in daily practice. Cancer, 87:118, 1999.
4. Bonner RB, Liebert M, Hurst RE, Grossman HB, Bane BL and Hemstreet GP 3rd: Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Cancer Epidemiol Biomarkers, Prev 5:971, 1996.
5. Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ: Long-term follow-up of patients treated with 1 or 2 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol, 144:652, 1990.
6. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, et al: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res, 57:1217, 1997.
7. Decensi A, Bruno S, Costantini M, Torrisi R, Curotto A, Gatteschi B, et al: Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst, 86:138, 1994.
8. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL: Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology, 50:882, 1997.
9. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med, 331:1259, 1994.
10. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD: Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol, 135:920, 1986.
11. Fradet Y and Lockhart C: Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt. Can J Urol, 4:400, 1997.
12. Freeman JA, Tarter TA, Esrig D, Stein JP, Elmajian DA, Chen SC, et al: Urethral recurrence in patients with orthotopic ileal neobladders. J Urol, 156:1615, 1996.
13. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer Statistics, 2000. CA Cancer J Clin, 50:7, 2000.
14. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, et al: p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res, 4:829, 1998.
15. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC: Telomere reduction in human colorectal carcinoma and with ageing. Nature, 346:866, 1990.
16. Hautmann RE, Paiss T, de Petriconi R: The ileal neobladder in women: 9 years of experience with 18 patients. J Urol, 155:76, 1996.
17. Hautmann RE, DePetriconi R, Gottfried HW, Kleinschmidt K, Mattes R, Paiss T: The ileal neobladder: complications and functional results in 363 patients after 11 years of follow-up. J Urol, 161:422, 1999.
18. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al: Superficial bladder cancer: progression and recurrence. J Urol, 130:1083, 1983.
19. Heney NM: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am, 19:429, 1992.
20. Iselin CE, Robertson CN, Webster GD, Vieweg J, Paulson DF: Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer? J Urol, 158:2123, 1997.
21. Johnston B, Morales A, Emerson L, Lundie M: Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol, 158:2098, 1997.
22. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM: Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol, 150:60, 1993.
23. Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL: Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest, 91:69, 1993.
24. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med, 325:1205, 1991.
25. Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol, 151:21, 1994.
26. Lamm DL, Herr H, Jakse G, Kuroda M, Mostofi FK, Okajima E, et al: Updated concepts and treatment of carcinoma in situ. Urol Oncol, 4:130, 1998.
27. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al: Maintenance BCG immunotherapy in recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma: a randomized Southwest Oncology Group study. J Urol, 163: 1124, 2000.
28. Lampel A, Fisch M, Stein R, Schultz-Lampel D, Hohenfellner M, Eggersmann C, et al: Continent diversion with the Mainz pouch. World J Urol, 14:85, 1996.
29. Landman J, Chang Y, Kavaler E, Droller MJ, Liu, BC: Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology, 52:398, 1998.
30. Lerner SP, Skinner E, Skinner DG: Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am, 19:713, 1992.
31. Lerner SP, Skinner DG, Lieskovsky G, Boyd SD, Groshen S, Ziogas A, et al: The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol, 149:758, 1993.
32. Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala A, et al: Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol, 155:1241, 1996.
33. Murphy WM: Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol, 21:886, 1990.
34. International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico (CUETO) group: Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet, 354:533, 1999.
35. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol, 149:749, 1993.
36. Ramakumar S, Bhuiyan J, Besse JA, Roberts, SC, Wollan, PC, Blute, ML, et al: Comparison of screening methods in detection of bladder cancer. J Urol, 161:388, 1999.
37. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair, WR, et al: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst, 85:53, 1993.
38. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al: Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol, 152:388, 1994.
39. Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, et al: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol, 154:379, 1995.
40. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, et al: Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology, 50:349, 1997.
41. Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, De Vries S, et al: Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am J Pathol, 144:756, 1994.
42. Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldman FM: Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. Int J Cancer, 64:99, 1995.
43. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, et al: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol, 158:801, 1997.
44. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A: Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol, 162:53, 1999.
45. Slaton JW, Dinney CPN, Veltri RW, Miller MC, Liebert M, O'Dowd GJ, et al: Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol, 158:806, 1997.
46. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, et al: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol, 156:363, 1996.
47. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: Short and long-term follow-up. J Urol, 161:1120, 1999.
48. Stampfer DS, Carpinito GA, Rodriguez Villanueva J, Willsey LW, Dinney CP, Grossman HB, et al: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol, 159:394, 1998.
49. Stein JP, Grossfeld GD, Freeman JA, Esrig D, Ginsberg DA, Cote RJ, et al: Orthotopic lower urinary tract reconstruction in women using the Kock ileal neobladder: updated experience in 34 patients. J Urol, 158:400, 1997.
50. Stein JP, Esrig D, Freeman JA, Grossfeld GD, Ginsberg DA, Cote RJ, et al: Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology, 51:951, 1998.
51. Stockle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, et al: Adjuvant polychemotherapy of nonorgan-confmed bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol, 153:47, 1995.
52. Studer UE, Danuser H, Merz VW, Springer JP, Zingg EJ: Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol, 154:49, 1995.
53. Studer UE, Hautmann RE, Hohenfellner M, Mills RD, Okada Y, Rowland RG, et al: Indications for continent diversion after cystectomy and factors affecting long-term results. Urol Oncol, 4:172, 1998.
54. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, et al: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol, 155:1233, 1996.
55. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ: Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol, 154:1719, 1995.
56. Turner WH, Danuser H, Moehrle K, Studer UE: The effect of nerve sparing cystectomy technique on postoperative continence after orthotopic bladder substitution. J Urol, 158:2118, 1997.
57. Vogelzang NJ, Stadler WM: Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology, 53:243, 1999.
58. Zieger K, Wolf H, Olsen PR, Hojgaard K: Long-term survival of patients with bladder tumours: the significance of risk factors. Br J Urol, 82:667, 1998.